Search Results
Oct 28, 2025, 05:05 ET LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE
evaluating LT3001 (intravenous Odatroltide) in patients with acute ischemic stroke. Results from this China-based study were presented by Dr. Shuya Li, Chief Neurologist at Beijing Tiantan Hospital, during an oral presentation at the 17th World Stroke Congress (WSC 2025) held in Barcelona, Spain.
More news about: Lumosa Therapeutics Co., Ltd.
Oct 28, 2025, 04:20 ET LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE
evaluating LT3001 (intravenous Odatroltide) in patients with acute ischemic stroke. Results from this China-based study were presented by Dr. Shuya Li, Chief Neurologist at Beijing Tiantan Hospital, during an oral presentation at the 17th World Stroke Congress (WSC 2025) held in Barcelona, Spain.
More news about: Lumosa Therapeutics Co., Ltd.
Oct 27, 2025, 15:26 ET Jiuzi Holdings, Inc. se asocia con la Fundación SOLV en una iniciativa de Bitcoin
y cumplimiento de las regulaciones de la Comisión de Bolsa y Valores de EE.UU. (SEC) y los requisitos de cotización en Nasdaq. Li Tao, consejero delegado de Jiuzi Holdings, Inc., declaró: "Esta alianza marca un avance transformador, fortaleciendo nuestra estrategia de bóveda de
More news about: Jiuzi Holdings, Inc
Oct 27, 2025, 13:35 ET Jiuzi Holdings, Inc. s'associe à la Fondation SOLV dans le cadre d'une initiative de valeur totale verrouillée en Bitcoin de 2,8 milliards de dollars visant à faire progresser sa stratégie de trésorerie en cryptomonnaies
réglementations de la Securities and Exchange Commission (SEC) des États-Unis et les conditions d'admission à la cote du NASDAQ. M. Li Tao, directeur général de Jiuzi Holdings, Inc. a déclaré : « Ce partenariat marque une étape transformatrice qui renforce notre stratégie de coffre-fort
More news about: Jiuzi Holdings, Inc
Oct 27, 2025, 12:24 ET Global Times: 'Ability to reform is one of CPC's most notable strengths': Japanese scholar on China studies
pioneers in their pursuit of national prosperity and people's happiness. When asked about his most admired early CPC members, Ishikawa spoke highly of Li Hanjun (1890-1927), praising his high level of Marxist theory and his efforts to integrate Marxism with China's revolutionary movement.
More news about: Global Times
Oct 27, 2025, 09:23 ET Nature's Miracle ("NMHI") Opened Office in Tokyo for the Tokenization Opportunities in Japan
Mr. Tie "James" Li, Chairman and CEO of Nature's Miracle Holding Inc said: "We are delighted to welcome Mr. Morimoto to the Nature's Miracle team, given his connection and
More news about: Nature's Miracle Holding Inc.
Oct 27, 2025, 09:00 ET Shanton Pharma Completes EOP2 Meeting with US FDA for Refractory Gout Program
"This End-of-Phase 2 meeting is a crucial milestone for our refractory gout program" says Dr. Bing Li, Shanton's CEO, "as it provides alignment with FDA on our upcoming Phase 3 pivotal program, including protocol, trial design, patient population, dose
More news about: Shanton Pharma
Oct 27, 2025, 09:00 ET Shanton Pharma Completes EOP2 Meeting with US FDA for Refractory Gout Program
"This End-of-Phase 2 meeting is a crucial milestone for our refractory gout program" says Dr. Bing Li, Shanton's CEO, "as it provides alignment with FDA on our upcoming Phase 3 pivotal program, including protocol, trial design, patient population, dose
More news about: Shanton Pharma
Oct 27, 2025, 08:50 ET Global Sources Sports & Outdoor Officially Opens
Lierence Li
More news about: Global Sources
Oct 27, 2025, 07:15 ET Jiuzi Holdings, Inc. Partners with SOLV Foundation on $2.8B TVL Bitcoin Initiative to Advance Crypto Treasury Strategy
governance, and compliance with U.S. Securities and Exchange Commission (SEC) regulations and Nasdaq listing requirements. Mr. Li Tao, Chief Executive Officer of Jiuzi Holdings, Inc., stated: "This partnership marks a transformative step forward, strengthening our Bitcoin vault
More news about: Jiuzi Holdings, Inc
Oct 27, 2025, 07:15 ET Jiuzi Holdings, Inc. Partners with SOLV Foundation on $2.8B TVL Bitcoin Initiative to Advance Crypto Treasury Strategy
governance, and compliance with U.S. Securities and Exchange Commission (SEC) regulations and Nasdaq listing requirements. Mr. Li Tao, Chief Executive Officer of Jiuzi Holdings, Inc., stated: "This partnership marks a transformative step forward, strengthening our Bitcoin
More news about: Jiuzi Holdings, Inc
Oct 27, 2025, 07:00 ET China's NMPA Grants Breakthrough Therapy Designation for Anti-CTLA-4 Antibody Candidate Gotistobart (BNT316/ONC-392)
[email protected] 1 Houston KA, Henley SJ, Li J, White MC and Richards TB, Lung Cancer, 86:22-28, 2014.2 Hu S, Zhang W, Guo Q, Ye J, Zhang D, Zhang Y, Zeng W, Yu D, Peng J, Wei
More news about: OncoC4
Oct 27, 2025, 05:00 ET Baidu to Host Baidu World, the Annual Flagship Technology Conference, on Nov 13, 2025
of the main session include: Co-founder, Chairman, and Chief Executive Officer Robin Li Chief Technology Officer Dr. Haifeng Wang Executive vice president, president of AI Cloud
More news about: Baidu, Inc.
Oct 27, 2025, 04:00 ET Best Deal to You. Best Gift to the Planet: Jackery partners with Greenspark this Black Friday to turn great deals into real climate action
Media enquiries: Jiatong Li[email protected]+4915223970329
More news about: Jackery
Oct 26, 2025, 16:56 ET Ribo kriegt von der EMA den Status als Orphan Drug für das siRNA-Therapeutikum RBD1016 gegen Hepatitis-Delta-Virus-Infektion (HDV)
Einstufung ist ein wichtiger Meilenstein in Sachen Regulierung, der die Entwicklung und das kommerzielle Potenzial von RBD1016 verbessert", sagt Dr. Li-Ming Gan, Co-Geschäftsführer und globaler Leiter der Forschungs- und Entwicklungsabteilung bei Ribo. „Das bestätigt unsere Strategie, mit innovativer
More news about: Ribo Life Science
Oct 26, 2025, 16:53 ET Ribo obtient de l'EMA la désignation de médicament orphelin pour le pARNi thérapeutique RBD1016 contre l'infection par le virus de l'hépatite Delta (VHD)
Cette désignation est une étape réglementaire importante qui renforce le potentiel de développement et de mise sur le marché du RBD1016 », déclare le Dr Li-Ming Gan, Co-CEO et responsable mondial de la R&D chez Ribo. « Elle valide notre stratégie consistant à cibler des maladies graves dont les besoins
More news about: Ribo Life Science
Oct 26, 2025, 14:21 ET SmallRig et MINA co-accueillent le 14ème Festival international du film mobile en Australie : 57 films mobiles de 21 pays débutent à Melbourne
l'équipement, à l'exposition et aux partenariats créatifs dans plus de 160 pays. « Nous transformons les visions des créateurs en réalité », a déclaré Li Dan, représentant de SmallRig. « Ce programme incarne notre engagement à « Free Your Dream », permettant aux conteurs de repousser les frontières. »
More news about: SmallRig
Oct 26, 2025, 14:16 ET Das 14. MINA International Smartphone Film Festival war von SmallRig, einem weltweit führenden Anbieter von innovativen Imaging-Lösungen, mitveranstaltet worden.
stung, Exposition und kreativen Partnerschaften in mehr als 160 Ländern zu erweitern."Wir verwandeln die Visionen der Schöpfer in Wirklichkeit", betonte Li Dan, Vertreter von SmallRig. "Dieses Programm verkörpert unser Engagement f ü r 'Befreien
More news about: SmallRig
Oct 26, 2025, 10:24 ET Nexteer ने इंजीनियरिंग सपोर्ट, परीक्षण और सत्यापन क्षमताओं को उन्नत करने के लिए Mexico Technical Center खोला
नियंत्रण चुनौतियों का समाधान करती है, जिसमें BMW, Ford, GM, RNM, Stellantis, Toyota और VW शामिल होने के साथ-साथ भारत और चीन में BYD, Xiaomi, ChangAn, Li Auto, Chery, Great Wall, Geely, Xpeng और अन्य शामिल हैं। www.nexteer.com
More news about: Nexteer Automotive
Oct 26, 2025, 09:09 ET SmallRig and MINA Co-Host 14th International Mobile Film Festival in Australia: 57 Mobile Films from 21 Countries Debut in Melbourne
expand access to equipment, exposure, and creative partnerships across more than 160 countries. "We're turning creators' visions into reality," said Li Dan, SmallRig representative. "This program embodies our commitment to 'Free Your Dream'—empowering storytellers to push boundaries."
More news about: SmallRig
Oct 26, 2025, 03:53 ET WuXi AppTec Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025 Backlog for Continuing Operations Up 41.2% YoY Further Raises 2025 Full-year Guidance
RMB5.0-6.0 billion to RMB8.0-8.5 billion. Management Comment Dr. Ge Li, Chairman and CEO of WuXi AppTec, said, "Reflecting robust customer demand and the strength of our unique CRDMO business model, WuXi AppTec delivered
More news about: WuXi AppTec
Oct 25, 2025, 04:02 ET Nexteer、エンジニアリング・サポート、テスト、検証能力の向上を目指してMexico Technical Centerを開設
リング・システム、ステアリング・コラムおよび中間シャフト、駆動系システム、ソフトウェア・ソリューション、ブレーキ・バイ・ワイヤなど、バイ・ワイヤによるシャーシ制御をサポートしています。同社は、BMW、Ford、GM、RNM、Stellantis、Toyota、VWなど世界中のグローバルおよび国内OEM、およびBYD、Xiaomi、ChangAn、Li Auto、Chery、Great Wall、Geely、Xpengなどインドと中国の自動車メーカー向けに、電動化、ソフトウェア/コネクティビティ、ADAS/自動運転、シェアード・モビリティなど、あらゆるメガトレンドにおけるモーション・コントロールの課題を解決しています。
More news about: Nexteer Automotive
Oct 24, 2025, 17:37 ET Ribo obtiene la designación de fármaco huérfano de la EMA para el siRNA terapéutico RBD1016
II."Esta designación constituye un hito regulatorio significativo que potencia el desarrollo y el potencial comercial de RBD1016", afirmó el Dr. Li-Ming Gan, coconsejero delegado y director global de I+D de Ribo. "Valida nuestra estrategia de abordar enfermedades graves con una alta demanda insatisfecha
More news about: Ribo Life Science
Oct 24, 2025, 16:30 ET PINTEC Announces Changes in the Board of Directors
committed to enabling innovative financial and digital solutions for businesses worldwide, today announced that its directors, Mr. Chao Chen and Mr. Tixin Li, resigned from their respective roles on the board of directors of the Company (the "Board"). Their resignations did not result from any disagreement
More news about: Pintec Technology Holdings Limited
Oct 24, 2025, 05:55 ET Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection
development. "This designation is a significant regulatory milestone that enhances the development and commercial potential of RBD1016" says Dr. Li-Ming Gan, Co-CEO and Global Head of R&D at Ribo. "It validates our strategy of targeting severe diseases with high unmet need through innovative
More news about: Ribo Life Science